Bicycle Therapeutics plc Cash Flow Conversion Efficiency
Bicycle Therapeutics plc cash flow conversion efficiency. Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has a cash flow conversion efficiency ratio of -0.097x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.61 Million ≈ $-57.99 Million USD) by net assets (€510.25 Million ≈ $596.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bicycle Therapeutics plc (2018–2025)
Cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2025. This chart illustrates how Bicycle Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bicycle Therapeutics plc (50BA) share price today for real-time trading data and today's change.
Bicycle Therapeutics plc Cash Flow Conversion Ratio Explained
Bicycle Therapeutics plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bicycle Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics plc ranked by their cash flow conversion efficiency. Also see 50BA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goodluck India Limited
NSE:GOODLUCK
|
0.037x |
|
EIH Associated Hotels Limited
NSE:EIHAHOTELS
|
0.023x |
|
Zhejiang Lianxiang Smart Home
SHG:603272
|
0.001x |
|
Lithium Royalty Corp
TO:LIRC
|
-0.001x |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
-0.097x |
|
Sunjuice Holdings Co Ltd
TW:1256
|
0.020x |
|
SillaJen Inc
KQ:215600
|
-0.040x |
|
Iones Co. Ltd
KQ:114810
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2025. Review Bicycle Therapeutics plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
€-249.68 Million ≈ $-291.90 Million |
-0.409x | -97.07% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
€-164.72 Million ≈ $-192.58 Million |
-0.208x | -76.51% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
€-43.65 Million ≈ $-51.03 Million |
-0.118x | +63.00% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
€-86.11 Million ≈ $-100.67 Million |
-0.318x | -644.30% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
€-14.79 Million ≈ $-17.30 Million |
-0.043x | +77.07% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
€-17.79 Million ≈ $-20.80 Million |
-0.186x | +39.30% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
€-28.61 Million ≈ $-33.45 Million |
-0.307x | -182.21% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
€-26.08 Million ≈ $-30.49 Million |
0.373x | -- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more